In line with this decision, the company said it will reduce its workforce by 50 percent. In the discontinued Phase II study, FIRCE-1, San Carlos, California-based Cargo was testing firicabtagene ...
The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback